Literature DB >> 2154955

Reductive activation of potential antitumor bis(aziridinyl)benzoquinones by xanthine oxidase: competition between oxygen reduction and quinone reduction.

K J Lusthof1, W Richter, N J de Mol, L H Janssen, W Verboom, D N Reinhoudt.   

Abstract

The reduction of a series of 2,5-bis(1-aziridinyl)-1,4-benzoquinone (BABQ) derivatives with various 3,6 substituents by the enzyme xanthine oxidase has been studied. The reduction rate has been assayed by measuring the rate of reduction of cytochrome c, which is very efficiently reduced by reduced BABQ species. Under nitrogen, the reduction rate correlated with the quinone reduction potential and steric parameters. Comparing reduction rates under nitrogen and air demonstrates that at BABQ concentrations greater than 25 microM the competition for electrons from xanthine oxidase between oxygen and the BABQ derivative is dominated by the latter. This is also confirmed by the effect of superoxide dismutase (SOD): in the presence of a BABQ derivative, cytochrome c reduction can be totally inhibited by SOD, although the required amount of SOD depends on the redox potential of the quinones. This indicates that SOD causes the equilibrium between semiquinone and superoxide to shift, resulting in a decrease of the semiquinone concentration. It is concluded that reduction by xanthine oxidase is a simple and effective method for reducing aziridinylbenzoquinones.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2154955     DOI: 10.1016/0003-9861(90)90561-c

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  2 in total

1.  Quinone-enhanced sonochemical production of nitric oxide from s-nitrosoglutathione.

Authors:  Antonio E Alegría; Francisco J Dejesús-Andino; Pedro Sanchez-Cruz
Journal:  Ultrason Sonochem       Date:  2008-05-24       Impact factor: 7.491

2.  Indoloquinone EO9: DNA interstrand cross-linking upon reduction by DT-diaphorase or xanthine oxidase.

Authors:  M Maliepaard; A Wolfs; S E Groot; N J de Mol; L H Janssen
Journal:  Br J Cancer       Date:  1995-04       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.